Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 312

The DOI matches its OpenAlex record.

Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)

Ulrich Gatzemeier, Anna Pluzanska, A. Szczęsna, Eckhard Kaukel, Jaromı́r Roubec, U. Brennscheidt, F. De Rosa, B. Mueller, Joachim von Pawel·2004·Journal of Clinical Oncology

Abstract

7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation inhibitor with single-agent antitumor activity and has shown additive effects when added to chemotherapy in preclinical models. TALENT was a placebo-controlled study in patients (pts) with previously untreated advanced NSCLC to receive erlotinib at 150mg/d or placebo (PBO) with 6 cycles of gemcitabine and cisplatin (GC) followed by monotherapy. The primary endpoint was duration of survival with secondary efficacy endpoints of: time to progression, response rate, duration of response (using RECIST); pharmacokinetic and pharmacodynamic parameters; quality of life (using the Lung Cancer Symptom Scale). EGFR and HER2 expression rates were also assessed. A standard safety analysis was done. Methods: Chemotherapy was given for a maximum of 6 cycles after which patients continued on study drug until disease progression (PD). Treatment with study drug beyond PD was permitted. Eligibility criteria for both parts of the study included: chemo-naive patients with unresectable stage III or IV NSCLC; age ≥18 years and ECOG PS of 0–1. Results: A total of 1172 pts were enrolled from 164 sites worldwide. The demographic and disease characteristics were well balanced across the two treatment groups. There were no statistically significant differences in overall survival (OS), time to progression (TTP) as described in the table below and quality of life (time to symptomatic progression [TSP]). The toxicity profile of erlotinib combined with GC was not significantly inferior to GC alone, with the exception of increased incidences of grade 3/4 diarrhea (<1% placebo vs. 6% erlotinib) and grade 3/4 skin rash (<1% placebo vs. 10% erlotinib). Conclusions: Erlotinib in combination with GC did not improve survival or other treatment outcomes in patients with advanced NSCLC. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche Lilly AstraZeneca Merck; Eli Lilly; AstraZeneca; Bristol-Myers Squibb

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

OpenAlex · 10.1200/jco.2004.22.14_suppl.7010

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 312

Metadata

Authors
Gatzemeier, U., Pluzanska, A., Szczęsna, A., Kaukel, E., Roubec, J., Brennscheidt, U., Rosa, F. D., Mueller, B., & von Pawel, J.
Venue
Journal of Clinical Oncology
Publisher
Lippincott Williams & Wilkins
Published
2004-07-15
Volume
22
Issue
14_suppl
Pages
7010-7010
ISSN
0732-183X (ISSN-L)
OpenAlex
W2242848604
Cited by
312
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). https://app.cochat.ai/papers/10.1200/jco.2004.22.14_suppl.7010
The paper
Gatzemeier, U., Pluzanska, A., Szczęsna, A., Kaukel, E., Roubec, J., Brennscheidt, U., Rosa, F. D., Mueller, B., & von Pawel, J. (2004). Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.22.14_suppl.7010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.